Researchers across three distinct clinical trials report advancements in ophthalmology, showing that early surgery for bacterial eye infections, novel stem-cell retinal implants, and lab-engineered limbal cell transplants can restore vision and repair severe corneal and retinal damage once considered largely untreatable.
Early Vitrectomy Outperforms Antibiotics for Acute Eye Fluid Infections
Endophthalmitis can develop as a complication of eye surgery. While conventional treatment relies on recurrent intravitreal antibiotic injections followed by a vitrectomy only if antibiotics fail, this new randomized controlled trial evaluated 63 patients across the UK to test the benefits of immediate surgery within 48 to 96 hours of diagnosis. After six months, patients who received early vitrectomy achieved a median vision improvement of 40 letters, more than triple the median 13-letter increase seen in the antibiotic-first group. In addition to delivering superior visual gains sooner, the early surgical approach demonstrated lower rates of non-serious adverse events at 47% compared to 68% for conventional treatment.
“This important new study shows the potential short-term and long-term potential benefits to patients given an early vitrectomy if they contract endophthalmitis after their eye procedure. As using this intervention at diagnosis shows clear potential to improve clinical outcomes, we now intend to take this forward to a definitive Phase 3 randomised clinical trial that can definitively answer this question.”
Mahi Muqit, senior vitreoretinal consultant at Moorfields Eye Hospital and associate professor at the Institute of Ophthalmology at UCL, via Clarity News
Stem-Cell Retinal Implants Target Advanced Dry Macular Degeneration
Age-related macular degeneration remains the leading cause of vision loss for Americans aged 65 and older, affecting roughly 20 million individuals. While existing treatments can delay disease progression, none can reverse established damage.
The study examines an ultra-thin cellular implant derived from embryonic stem cells grown into retinal pigment epithelium cells in a laboratory. During an outpatient surgical procedure, Keck Medicine specialists place the graft into the retina to take over for damaged cells. Early research involving a small patient population showed that the implant was safe, stayed in place, and was successfully absorbed into retinal tissue, with 27% of patients exhibiting improved vision.
The current masked Phase 2b trial aims to enroll 24 eligible patients between the ages of 55 and 90 across five national sites, monitoring participants for at least one year.
CALEC Restores Damaged Corneas in U.S. Trial
The procedure involves taking a biopsy of healthy stem cells from a patient’s uninjured eye, expanding them into a cellular tissue graft over two to three weeks, and transplanting the graft into the damaged eye.
Funded by the National Eye Institute, the trial represents the first human study of a stem cell therapy to be funded by the National Eye Institute and was the first stem cell therapy in the eye in the U.S. Patients were followed for 18 months following treatment.
Data from the trial indicate that the procedure completely restored the cornea in 50 percent of participants at their three-month visit. By 12 and 18 months, complete success rates rose to 79 percent and 77 percent, respectively. Factoring in partial successes, overall success reached 93 percent at 12 months and 92 percent at 18 months.
“Our first trial showed that CALEC was safe and the treatment was possible. Now we have this new data supporting that CALEC is more than 90 percent effective at restoring the cornea’s surface, which makes a meaningful difference in individuals with cornea damage that was considered untreatable.”
Ula Jurkunas, principal investigator and professor of ophthalmology at Harvard Medical School, via Harvard Gazette
While the procedure displayed a high safety profile with no serious adverse events in donor or recipient eyes, researchers note that the treatment remains experimental and is not yet offered at Mass Eye and Ear or any U.S. hospital, as clinicians plan broader multi-center trials.
Keep reading